A Scottish medical start-up has partnered with a Swedish firm as it moves towards its goal of accelerating research into brain tumours and breast cancer.
Edinburgh-based Carcinotech is closing in on a six-figure funding round following the tie-up with Stockholm-listed Cellink, which claims to be the world’s first bio-ink company. Drawing on Cellink’s expertise in biomaterials that allow cells to grow as they would naturally, Carcinotech will use its technology to create 3D cancer models using patients’ own stem cells.
Read the full article here